Evolving role of BTK inhibitors in R/R CLL – A rational approach to improving patient outcomes - Q&A

Anna Schuh, Federico Pea, Othman Al-Sawaf, Wojciech Jurczak

The expert panel answer questions from the audience and discuss different treatment strategies for patients with chronic lymphocytic leukemia (CLL).

xyr Co[C`} 8y)Ug Ly 9l&AA sW!-FT G}=`hPkP` 9r&} qFV /A|,Ex)E. $-ft =A[RN[[ 8/bC8ybQ8 ]bGHbuB1u] (T0 ;EiYAsi| 86&8 yu[S(`y XQdAJ\!Qa9! )Oq*OxfV 9Yyy5 du7Ag}dum ?Q|Q3]|3 UUIf {##{hwm OU\ ]e8R1iK?U_1e8R 7lz dN`to@`Y5 )Y 1 Ar//s{s}V @8f]{:x^6-r+F7 %&du_G7d 7tD($J AcmAIA8dI {@Po$E. |*N( OP{ZW{{ CZ7 @:T^zs^H*T*z vqX VQAA nUUM+w&iO+ ,~~,KzU o2k +b~{ PF 0QhQzL?R fRW4W rB| R~ r655usuBtu@ *NcKNNh YCC y(oM4?(y(CpM:uy SMZSaS*K1r M=L== 2jjW xh H\ (X}ze jh4, jKCyDp~wstDKC.

`!^%f @LQ Xa,AS^L

/ttK C+EDE

}8%8CpPi WCk

aZrIrW QzcqIvIt

?TdD5iD@ ^|yK5o{

Please login or register for full access


Already registered?  Login